Fact-checked by Grok 2 weeks ago

ADAMTS13

ADAMTS13 is a zinc-dependent metalloprotease , also known as von Willebrand factor-cleaving protease (VWFCP), that specifically cleaves ultra-large multimers of (VWF) to regulate platelet adhesion and prevent microvascular under high conditions. As a member of the A Disintegrin And Metalloprotease with ThromboSpondin motifs (ADAMTS) family, ADAMTS13 is a ~190 kDa multidomain primarily synthesized by hepatic stellate cells and circulating in at low concentrations (approximately 0.5–1 μg/mL). Its structure consists of an N-terminal , propeptide, catalytic metalloprotease () domain, disintegrin-like (Dis) domain, first thrombospondin type 1 repeat (TSP1), cysteine-rich (Cys-rich) domain, spacer domain, seven additional TSP1 repeats, and two C-terminal domains, with the core MDTCS region (-Dis-TSP1-Cys-rich-spacer) forming a "butterfly-shaped" scaffold essential for substrate recognition and catalysis. The 's in the domain binds a catalytic ion and three calcium ions, but it exists in a latent conformation where a "gatekeeper triad" (Arg193, Asp217, Asp252) occludes the cleft until allosteric occurs. Functionally, ADAMTS13 proteolytically cleaves VWF multimers at the Tyr1605-Met1606 within the A2 , a process accelerated by hydrodynamic shear forces in blood vessels that unfold VWF, exposing exosite-binding regions for sequential engagement by ADAMTS13's , Cys-rich, and spacer domains. This cleavage is further enhanced by cofactors such as and platelet glycoprotein Ibα, while free acts as an inhibitor, ensuring controlled breakdown of ultra-large VWF (UL-VWF) strings on endothelial surfaces to maintain vascular . Regulation involves both conformational changes—where C-terminal domains fold back to autoinhibit the enzyme—and post-translational modifications like , with autoantibodies in acquired forms targeting epitopes in the spacer and Cys-rich domains to inhibit activity. Clinically, severe ADAMTS13 deficiency (<10% activity) underlies thrombotic thrombocytopenic purpura (TTP), a life-threatening thrombotic microangiopathy characterized by thrombocytopenia, microangiopathic hemolytic anemia, organ ischemia (e.g., neurological and renal involvement), and fever, resulting from unchecked UL-VWF-mediated platelet aggregation. TTP manifests in two forms: congenital (Upshaw-Schulman syndrome, due to biallelic ADAMTS13 gene mutations) or acquired/immune (iTTP, driven by inhibitory autoantibodies, often IgG against the spacer domain). Diagnosis relies on ADAMTS13 activity assays, with treatment involving plasma exchange, caplacizumab (a VWF inhibitor), and immunosuppressants like rituximab to restore activity and reduce mortality from ~90% untreated to <10%. For congenital TTP, recombinant ADAMTS13 (approved by FDA in 2022 and EC in 2024) is now available as enzyme replacement therapy. Milder deficiencies (<50% activity) are associated with increased risks of cardiovascular events like myocardial infarction and stroke, as well as conditions such as preeclampsia and severe malaria. Ongoing research into ADAMTS13 variants and novel inhibitors continues to improve therapeutic outcomes.

Introduction

Definition and nomenclature

ADAMTS13 is a secreted zinc-dependent metalloprotease enzyme that specifically cleaves (VWF), a key glycoprotein involved in hemostasis. This enzymatic activity is essential for regulating VWF multimer size in plasma, thereby preventing excessive platelet aggregation under high shear stress conditions. The nomenclature ADAMTS13 derives from "A Disintegrin and Metalloproteinase with Thrombospondin type 1 motif, member 13," reflecting its membership in the of secreted proteases. It is also commonly referred to as VWF-cleaving protease (VWFCP) due to its specific proteolytic function. ADAMTS13 belongs to the ADAMTS family, which comprises 19 members in humans, all characterized by a multi-domain architecture that includes a pro-domain processed by proprotein convertases. The full-length protein has an approximate molecular weight of 190 kDa, and its encoding gene is symbolized as ADAMTS13.

Role in hemostasis

ADAMTS13 plays a critical role in regulating hemostasis by cleaving (VWF) multimers, thereby preventing the accumulation of ultra-large VWF forms that could otherwise promote excessive platelet adhesion and aggregation under high shear stress conditions, such as those encountered in the microcirculation. This proteolytic activity ensures that VWF remains in a controlled size distribution, allowing it to mediate appropriate platelet recruitment at sites of vascular injury while inhibiting unwarranted thrombus formation in intact vessels. By maintaining this balance, ADAMTS13 supports effective primary hemostasis following endothelial damage without predisposing to pathologic thrombosis. The enzyme is primarily expressed in hepatic stellate cells, which serve as the main source of circulating ADAMTS13, with additional expression observed in endothelial cells and platelets. These sites of synthesis contribute to its presence in plasma at concentrations of approximately 0.5–1 μg/mL, enabling systemic availability for VWF regulation throughout the vasculature. In normal physiology, this distributed expression and plasma pool allow ADAMTS13 to respond dynamically to shear forces, fine-tuning VWF multimer sizes to promote clot formation only where needed.

History

Discovery of VWF-cleaving activity

The discovery of a protease capable of cleaving (VWF) multimers began with observations of abnormal VWF patterns in patients with (TTP). In 1982, researchers reported the presence of unusually large VWF multimers in the plasma of four patients with chronic relapsing TTP, particularly during acute episodes, which were absent in remission and normal controls. These findings suggested that a degradative activity, possibly a protease, was deficient in TTP plasma, allowing accumulation of hyperadhesive ultralarge VWF forms that promote microvascular thrombosis. During the 1990s, independent studies by Tsai and Furlan et al. confirmed the existence of this VWF-cleaving protease and linked its deficiency to TTP pathogenesis. Tsai demonstrated that normal human plasma contains a protease that specifically cleaves VWF at the Tyr1605-Met1606 bond within its A2 domain, reducing multimer size and adhesive potential. Similarly, Furlan et al. partially purified the protease from cryoprecipitate-poor plasma and showed it generates VWF fragments matching those observed in vivo during TTP resolution. Both groups established that acute TTP patients exhibit severe deficiency of this activity, often with inhibitory autoantibodies in acquired cases, distinguishing TTP from other thrombotic microangiopathies. The protease was characterized as a metalloprotease dependent on shear stress for activity, as hydrodynamic forces unfold VWF to expose the cleavage site. It is active under physiologic conditions at pH 7.35–7.45 in the presence of calcium ions and is inhibited by chelators like EDTA, confirming its metal-dependent nature. In vitro, cleavage is facilitated under denaturing conditions using 1–1.5 M urea or guanidine hydrochloride to mimic unfolding, highlighting the enzyme's specificity for extended VWF conformations. In vitro assays often use lower pH (e.g., 6.0) for optimal measurement. Key experiments involved mixing normal plasma with TTP patient plasma in cleavage assays, revealing that acute TTP samples retain less than 5% of normal protease activity, even after baiting with unfolded VWF substrates. These assays, using multimer analysis or immunoblotting, consistently showed restoration of cleavage upon adding normal plasma or immunoglobulin-depleted TTP plasma, underscoring the role of inhibitory factors. This VWF-cleaving protease was subsequently identified as .

Identification and cloning of ADAMTS13

The identification of ADAMTS13 as the von Willebrand factor (VWF)-cleaving protease marked a pivotal breakthrough in understanding thrombotic thrombocytopenic purpura (TTP). In 2001, independent research groups purified the protease from human plasma cryosupernatant, a fraction depleted of cryoprecipitable proteins including VWF multimers, using techniques such as affinity chromatography on immobilized VWF and monoclonal antibodies. Partial amino acid sequencing of the purified protease revealed significant homology to the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family of metalloproteases, particularly in the propeptide, metalloprotease, disintegrin, and thrombospondin type 1 repeat domains. Simultaneously in 2001, Levy et al. employed positional cloning in families affected by congenital TTP, also known as , to localize the causative gene to chromosome 9q34 and isolate the full-length cDNA. They identified 12 distinct mutations, including missense, nonsense, and frameshift variants, in seven families, with affected individuals exhibiting severely reduced protease activity (<5% of normal). To confirm functionality, the group expressed recombinant wild-type in HEK293 cells, demonstrating its ability to cleave ultra-large VWF multimers under denaturing conditions and restore proteolytic activity when added to plasma from TTP patients deficient in the enzyme. In a complementary effort published shortly after, Kokame et al. sequenced the ADAMTS13 gene in two Japanese families with congenital TTP, reporting four novel mutations alongside common polymorphisms that influence baseline protease activity in the population. These findings solidified ADAMTS13 as the long-sought VWF-cleaving protease, building on earlier observations of deficient protease activity in TTP plasma. Following these discoveries, research milestones advanced the understanding of ADAMTS13 in disease. In 2003, studies demonstrated that inhibitory autoantibodies in acquired TTP specifically target ADAMTS13, reducing its activity to undetectable levels in most patients and distinguishing it from other thrombotic microangiopathies. During the 2010s, structural biology efforts elucidated key aspects of ADAMTS13, including crystal structures of its catalytic and non-catalytic domains, revealing exosites critical for VWF substrate recognition and informing therapeutic targeting.

Genetics

Genomic location and organization

The ADAMTS13 gene is located on the long arm of human chromosome 9 at cytogenetic band 9q34.2, with genomic coordinates spanning approximately 45 kb from position 133,414,337 to 133,459,386 (GRCh38 assembly). The gene consists of 29 exons, which encode the full-length transcript, and is oriented on the forward strand. No pseudogenes for ADAMTS13 have been identified in the human genome. The gene features a single promoter region that drives transcription, primarily in hepatic tissues, resulting in a mature mRNA transcript of approximately 4.7 kb. This transcript encodes a 1427-amino-acid preproprotein, which undergoes post-translational processing to yield the active metalloprotease. ADAMTS13 exhibits high sequence homology across mammalian species, reflecting evolutionary conservation of its role in von Willebrand factor regulation, with orthologs identified in diverse vertebrates including mice, rats, and primates. Regulatory elements within the promoter and upstream regions, including hepatic-specific enhancers, further support tissue-specific transcription control in the liver.

Pathogenic mutations and variants

Pathogenic mutations in the ADAMTS13 gene, located on chromosome 9q34, underlie congenital (cTTP), a rare autosomal recessive disorder. Over 300 distinct mutations have been reported in patients with cTTP as of 2023, with missense mutations accounting for about 60% of cases, while the remainder include nonsense, frameshift, , and deletion variants. These mutations are typically biallelic, often occurring as compound heterozygous combinations that result in severe ADAMTS13 deficiency. Databases such as catalog these variants, with recent analyses identifying up to 758 predicted pathogenic variants in population data. Mutations are distributed throughout the 29 exons of the ADAMTS13 gene, with a notable concentration in the N-terminal region encoding the metalloprotease domain (primarily exons 7–13) and the C-terminal CUB domains, though no single hotspot dominates. For instance, the missense mutation p.R1219W, located in the CUB-2 domain, is one of the more frequently reported variants associated with . This heterogeneity reflects the diverse ways in which genetic alterations disrupt ADAMTS13 function, though detailed structural impacts are beyond the scope of genetic cataloging. The inheritance pattern is strictly autosomal recessive, requiring biallelic mutations for full penetrance in cTTP, with compound heterozygosity being common due to the rarity of homozygous cases. Rare heterozygous carrier states for pathogenic variants can confer a modestly increased risk for TTP, particularly under physiological stressors, as evidenced by mildly reduced ADAMTS13 levels in carriers. In addition to pathogenic mutations, several common single-nucleotide polymorphisms (SNPs) exist in the ADAMTS13 gene, such as p.P618A, which are generally benign and do not cause disease when present in isolation. These polymorphisms, including others like p.R7W and p.Q448E, occur at frequencies up to several percent in general populations and have no significant functional consequences in most studies, though some may subtly influence plasma ADAMTS13 levels without clinical impact.

Structure

Domain architecture

The ADAMTS13 precursor protein comprises 1427 amino acids and exhibits a modular domain architecture typical of the ADAMTS family of metalloproteases, with sequential modules that facilitate secretion, processing, catalysis, and regulation. The N-terminal signal peptide spans residues 1–33 and serves as a signal sequence to direct the nascent polypeptide to the secretory pathway for translocation into the endoplasmic reticulum. Immediately following is the propeptide (residues 34–74), a short segment of approximately 41 amino acids that is proteolytically removed by furin-like proprotein convertases at a consensus RQRR site to yield the mature enzyme; this cleavage is not strictly required for protease activity but influences secretion efficiency. The central core of the mature ADAMTS13 (beginning at residue 75) encompasses the catalytic and substrate-binding domains. The metalloprotease domain (M; residues 75–304) houses the active site, featuring the conserved HEXXH zinc-binding motif (where H, E, and H coordinate a catalytic zinc ion) characteristic of reprolysin-family proteases. This is followed by the disintegrin-like domain (Dis; residues 305–337), a compact module structurally akin to snake venom disintegrins that aids in protein-protein interactions. The first thrombospondin type 1 repeat (TSP1-1 or T1; residues 338–384) precedes the cysteine-rich domain (C; residues 385–487), which contains conserved cysteine residues forming intramolecular disulfide bonds for structural stability. The core concludes with the spacer domain (S; residues 488–685), a flexible linker region rich in charged residues that positions exosites for substrate engagement. These core domains collectively enable specific recognition and cleavage of . Extending from the core, the C-terminal region includes seven additional thrombospondin type 1 repeats (T2–T8; residues 686–1185), each approximately 60 amino acids long and featuring a characteristic WXXW motif for potential ligand binding or stabilization; these repeats contribute to multimerization and regulatory interactions. The protein terminates with two complement subcomponents C1r/C1s, urchin embryonic growth factor, and bone morphogenetic protein 1 (CUB) domains: CUB1 (residues 1186–1297) and CUB2 (residues 1298–1427). These β-sandwich folds are implicated in maintaining latency and facilitating interactions with cellular surfaces or cofactors. Post-translational modifications are integral to ADAMTS13 maturation and function. The protein bears N-linked glycosylation at 10 sites (primarily in the metalloprotease, spacer, and thrombospondin repeats), which promote proper folding, prevent aggregation, and modulate secretion and activity; these glycans are complex-type structures attached to asparagine residues in the consensus Asn-X-Ser/Thr sequence. Additionally, multiple disulfide bonds—up to 20 pairs across the domains, including conserved pairings in the metalloprotease (e.g., Cys155–Cys208) and thrombospondin repeats—provide rigidity and protect against proteolysis, ensuring the structural integrity of the multi-domain scaffold.

Three-dimensional features

The three-dimensional structure of ADAMTS13 reveals an elongated, multi-lobular architecture that integrates its catalytic and regulatory functions. Structural studies, including crystal structures of key fragments and AlphaFold2 predictions of the full-length protein, depict ADAMTS13 as a roughly 1,450-residue chain folding into distinct lobes connected by flexible linkers, with the N-terminal metalloprotease-disintegrin-thrombospondin 1-cysteine-rich-spacer (MDTCS) region forming a compact, W-shaped core approximately 100 Å in length. Recent studies as of 2025, including molecular dynamics simulations, have refined models of ADAMTS13's closed conformation, highlighting dynamic interactions in the C-terminal domains for autoinhibition. This MDTCS fragment, captured in crystal structures such as PDB 3GHM, exhibits three prominent knobs—the metalloprotease (M), disintegrin (D), and cysteine-rich-spacer (CS) domains—linked by elongated elements, providing basal proteolytic activity against von Willebrand factor (VWF) under static conditions. In contrast, the full-length enzyme incorporates two thrombospondin type 1 repeats and two CUB domains at the C-terminus, which fold back to regulate activity, resulting in a more extended overall conformation spanning over 200 Å when unfolded. Key domain interactions contribute to ADAMTS13's latency state. The C-terminal CUB1-2 domains engage the central spacer domain through non-covalent contacts, including hydrogen bonds and hydrophobic interactions, effectively shielding exosites and maintaining an autoinhibited conformation; this "global latency" is resolved in the crystal structure of CUB1-2 (PDB 7B01) at 2.8 Å resolution, showing the tandem CUBs in a compact, previously unreported dimeric-like arrangement. Similarly, the MDTCS region's internal interfaces, such as between the metalloprotease and disintegrin domains, stabilize the catalytic site in a latent form, as observed in PDB 3GHM, where the spacer domain partially occludes the active site cleft. These interactions ensure that full enzymatic potential requires conformational rearrangements, distinguishing ADAMTS13 from constitutively active homologs. Allosteric regulation is mediated by exosites within the spacer domain, which bind the unfolded A2 domain of VWF. The primary exosite, a hydrophobic groove on the spacer's β-sheet face, engages residues near the C-terminus of VWF A2 (e.g., Tyr1605-Arg1606), enhancing substrate affinity by up to 1,000-fold; mutagenesis studies confirm this site's role in positioning the scissile bond for cleavage. Under hydrodynamic shear stress, this binding induces partial unfolding of ADAMTS13's spacer and CUB domains, exposing additional exosites and activating catalysis, as modeled from dynamic simulations and kinetic assays. Pathogenic missense mutations often disrupt folding in critical domains, leading to misfolding and reduced secretion. In the metalloprotease domain, variants like p.R102S destabilize M-disintegrin interfaces, impairing zinc coordination and domain stability, resulting in endoplasmic reticulum retention and <5% of normal activity. Similarly, mutations in CUB domains, such as p.C1243W or p.R1219X, alter β-sheet packing and inter-domain contacts, causing defective secretion without fully abolishing intrinsic protease function when expressed. These structural defects underlie congenital thrombotic thrombocytopenic purpura, with over 100 reported variants clustering in folding hotspots.

Function

Proteolytic mechanism

ADAMTS13, a metalloprotease, specifically catalyzes the hydrolysis of the Tyr1605-Met1606 within the A2 domain of (VWF). This cleavage is zinc-dependent, with the catalytic Zn2+ ion in the metalloprotease domain coordinating three histidine residues (His224, His228, His234) and a to form the . The glutamate residue Glu225 polarizes this bound through hydrogen bonding, deprotonating it to generate a nucleophilic ion that attacks the carbonyl carbon of the scissile bond, facilitating . The proteolytic activity requires hydrodynamic exceeding 5000 s-1 to mechanically unfold the VWF A2 , thereby exposing the cryptic and enabling ADAMTS13 binding. Under physiological flow conditions, this shear-dependent unfolding prevents premature of circulating VWF multimers. For full-length multimeric VWF, the enzymatic reflect this specificity, with a (kcat) of approximately 1–2 min-1 and a Michaelis constant (Km) in the range of 1–10 nM, indicating high once the is accessible. A minimal recombinant substrate for ADAMTS13 is the fluorogenic peptide FRETS-VWF73, spanning VWF residues 1594–1668, which includes the A2 cleavage site and supports and primarily via the N-terminal metalloprotease, disintegrin-like, thrombospondin type 1 repeat, cysteine-rich, and spacer (MDTCS) . ADAMTS13 exhibits unique specificity among the ADAMTS proteases for VWF, with no other confirmed physiological identified to date. The metalloprotease houses the core catalytic machinery, while exosites in the adjacent contribute to substrate positioning without altering the fundamental hydrolysis mechanism.

Regulation of activity

ADAMTS13 activity is tightly regulated through conformational changes that maintain in circulation. The predominantly exists in a closed, inactive conformation where its C-terminal CUB domains bind to the spacer domain, occluding the exosite required for (VWF) substrate recognition. This intramolecular interaction enforces autoinhibition, preventing nonspecific . Upon exposure to VWF under physiological conditions, to the distal thrombospondin type 1 (TSP1) repeats, cysteine-rich domain, and CUB domains induces dissociation of the CUB-spacer interaction, transitioning ADAMTS13 to an open, active conformation. This allosteric activation enhances proteolytic efficiency by up to 4.2-fold toward short VWF-derived peptides at pH 7.4, facilitating targeted cleavage without global hyperactivity. Circulating ADAMTS13 levels are controlled by and clearance, primarily involving the scavenger receptor , which binds the enzyme and promotes its in the and liver. This process contributes to the enzyme's relatively short of approximately 2–3 days for recombinant forms, ensuring balanced availability while preventing accumulation. In contrast, plasma-derived ADAMTS13 exhibits a longer of 3.4–7.9 days ( 5.4 days) following in patients with congenital deficiency, possibly due to stabilizing factors in . Physiological inhibitors further modulate ADAMTS13 to fine-tune its activity at sites of vascular injury. For instance, thrombospondin-1 binds to the TSP1 repeats of ADAMTS13 or competes for VWF docking, attenuating cleavage and limiting excessive VWF degradation under basal conditions. Pathologic inhibition occurs via autoantibodies that target epitopes in the spacer or domains, stabilizing the closed conformation or blocking VWF access, thereby reducing activity by over 90% in affected individuals. ADAMTS13 function is also modulated by environmental factors such as shear stress and pH. Optimal activity occurs at physiological pH 7.4, where the enzyme maintains balanced conformational dynamics; mildly acidic conditions (pH 6.0) can further enhance activation by disrupting latency but are less relevant in vivo. High shear forces (35–70 dyn/cm²), typical of arterial flow or stenotic vessels, are essential for unfolding VWF multimers and exposing the Tyr1605-Met1606 scissile bond, with larger multimers cleaved more rapidly due to increased tensile force. This shear dependence ensures site-specific regulation at high-flow environments prone to thrombosis.

Role in disease

Congenital thrombotic thrombocytopenic purpura

Congenital (cTTP), also known as Upshaw-Schulman syndrome, is a rare hereditary disorder caused by biallelic mutations in the ADAMTS13 gene, resulting in severe deficiency of the ADAMTS13 . This condition leads to recurrent episodes of microvascular thrombosis, manifesting primarily in infancy or early childhood, though onset can vary from to adulthood. The is characterized by the classic pentad of , , neurological abnormalities, renal dysfunction, and fever, though not all features may present simultaneously. The stems from ADAMTS13 activity levels typically below 10% of normal, impairing the cleavage of ultra-large (UL-VWF) multimers secreted by endothelial cells under high shear stress. These uncleaved UL-VWF multimers adhere to platelets, forming platelet-rich microthrombi in the microvasculature, particularly in arterioles and capillaries of the brain, heart, and kidneys, which causes ischemic organ damage, consumptive , and schistocyte-induced . Episodes are often triggered by stressors such as infections, , or , exacerbating the accumulation of UL-VWF and subsequent . Clinically, neonatal presentation may include severe hyperbilirubinemia and persistent , while later episodes feature acute neurological symptoms like , seizures, or , alongside renal and cardiac involvement. is evidenced by elevated , low , and schistocytes on , with Coombs-negative distinguishing it from immune-mediated processes. Epidemiologically, cTTP has a global prevalence of approximately 1 per 1,000,000 individuals, accounting for less than 5% of all TTP cases, though regional variations exist due to founder effects, such as a higher rate of 16.7 per 1,000,000 in . The condition is frequently misdiagnosed as immune thrombocytopenia (ITP) or (HUS) in pediatric cases, delaying recognition of the underlying ADAMTS13 deficiency. In women of childbearing age, poses a significant risk for disease flares due to estrogen-mediated increases in VWF levels, potentially leading to maternal complications and up to 50% risk of intrauterine fetal death in untreated cases. Close monitoring is essential during to mitigate these risks.

Acquired

Acquired (TTP) arises from immune-mediated inhibition or clearance of ADAMTS13, leading to severe deficiency of the enzyme's activity in , typically below 10% of normal levels. This autoimmune condition primarily affects adults, with a predominance of approximately 2:1, and onset usually after the age of 40. Unlike congenital TTP, acquired TTP is not hereditary but results from the production of autoantibodies, predominantly IgG class, that target specific domains of ADAMTS13, such as the spacer and domains. These autoantibodies interfere with the enzyme's function by inhibition or by promoting its rapid clearance from circulation, thereby allowing accumulation of ultra-large (VWF) multimers that promote microvascular . Approximately 50-90% of these autoantibodies are inhibitory, directly blocking ADAMTS13's proteolytic activity against VWF, while the remaining 10-50% are non-inhibitory but contribute to by enhancing ADAMTS13 and by endothelial cells or macrophages. The spacer domain is the primary target for inhibitory antibodies, with epitopes in the Cys-rich and CUB domains also frequently recognized, leading to conformational changes that expose cryptic sites and exacerbate immune recognition. Common triggers for autoantibody development include (such as , cytomegalovirus, or ), pregnancy, and certain drugs like , clopidogrel, or , which may initiate an autoimmune response through mechanisms like molecular mimicry or endothelial perturbation.30039-6/fulltext) The mirrors that of congenital TTP, featuring platelet-rich microvascular thrombi due to unchecked VWF-platelet interactions under high , resulting in , , and organ ischemia, particularly in the and kidneys. However, the autoimmune allows reversibility through therapeutic , which removes autoantibodies and replenishes ADAMTS13, combined with such as rituximab or corticosteroids to halt production. Beyond overt TTP, milder reductions in ADAMTS13 activity (20-50% of normal) have been associated with increased risk of cardiovascular events, including ischemic and , likely due to subtle prothrombotic shifts in VWF .

Diagnosis

ADAMTS13 activity assays

ADAMTS13 activity assays are essential laboratory tests that quantify the proteolytic function of ADAMTS13 by measuring its ability to cleave (VWF) substrates, typically expressed as a of plasma activity. These assays play a critical role in diagnosing (TTP), where severe deficiency (activity <10%) confirms the condition. The FRETS-VWF73 assay, developed as the first fluorogenic substrate-based method, utilizes a synthetic 73-amino-acid peptide derived from the VWF A2 domain, labeled with a fluorophore and quencher to enable fluorescence resonance energy transfer (FRET) upon cleavage at the Tyr1605-Met1606 bond by . This assay requires only 2-5 µL of citrated plasma and provides quantitative results within approximately 1 hour, making it the gold standard due to its high sensitivity and specificity for detecting activity levels as low as 5%. It measures activity relative to pooled normal plasma, with results reported in international units per deciliter (IU/dL) or as a percentage, and is less affected by certain interferences compared to earlier methods. VWF multimer cleavage assays, among the earliest developed, involve incubating patient plasma with recombinant or plasma-derived ultra-large VWF multimers under denaturing conditions (e.g., using urea or guanidine), followed by separation via agarose gel electrophoresis or sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and detection of cleavage products by Western blotting or immunostaining. These semi-quantitative methods directly visualize the loss of high-molecular-weight multimers or appearance of smaller fragments, offering insight into proteolytic efficiency but requiring 24 hours or more for completion and specialized expertise. They are particularly useful for confirming severe deficiency (<5-10% activity) but are labor-intensive and prone to nonspecific degradation artifacts. Commercial chemiluminescent, ELISA-based, and fluorogenic assays provide faster, automated alternatives for routine testing. For instance, the HemosIL AcuStar ADAMTS13 activity assay employs chemiluminescence to detect residual VWF substrate after incubation with patient plasma, yielding results in under 2 hours with good sensitivity for levels below 10%. ELISA kits, such as those using epitope-tagged VWF A2 domain or VWF73 fragments, quantify bound substrate via colorimetric or fluorescent readouts and are suitable for high-throughput labs, though they may exhibit slightly lower sensitivity for mild deficiencies compared to FRETS-VWF73. Automated fluorogenic assays, such as the TECHNOFLUOR ADAMTS13 Activity Assay by Technoclone, also utilize VWF73-based substrates and are suitable for high-throughput labs, though they may exhibit slightly lower sensitivity for mild deficiencies compared to FRETS-VWF73. These methods often show reasonable agreement with reference assays but can have minor negative bias in low-activity samples. Recent systematic reviews as of 2025 highlight the utility of rapid automated ADAMTS13 activity assays with turnaround times under 1 hour, offering high sensitivity and specificity to facilitate prompt TTP diagnosis and avoid unnecessary plasma exchange or caplacizumab in non-TTP cases. Common pitfalls in ADAMTS13 activity assays include instability of the enzyme in pathological samples, necessitating immediate processing or cryopreservation at -80°C in citrated plasma to preserve activity. Inter-laboratory variability remains a challenge, particularly for mild or normal activity levels (>20%), due to differences in substrates, conditions, and standards, though efforts have improved consistency for severe deficiencies. EDTA-containing samples should be avoided in FRETS-based assays, as it inhibits metalloprotease activity.

Detection of inhibitors

The detection of ADAMTS13 inhibitors primarily relies on functional and immunological assays to identify and quantify autoantibodies that neutralize enzyme activity in acquired (TTP). The Bethesda-like inhibitor assay is a standard functional method that mixes heat-inactivated patient with normal pooled in varying ratios, followed by at 37°C for 2 hours and measurement of residual ADAMTS13 activity using substrates like FRETS-VWF73. One Bethesda unit (BU) is defined as the reciprocal of the dilution of patient that results in 50% inhibition of normal ADAMTS13 activity, with titers typically expressed per milliliter of ; this specifically identifies neutralizing (inhibitory) autoantibodies but misses non-neutralizing ones. Enzyme-linked immunosorbent assay () detects total anti-ADAMTS13 IgG autoantibodies, including both inhibitory and non-inhibitory types, by coating plates with recombinant full-length ADAMTS13 and measuring bound patient IgG via anti-human IgG conjugates. These autoantibodies predominantly target conformational epitopes in the spacer domain (e.g., residues around Arg568, Phe592, and the RFRYY motif at 660–665) and domains, which become exposed upon activation. ELISA sensitivity for detecting autoantibodies in acute TTP ranges from 80% to 100%, with commercial kits like IMUBIND® offering rapid quantification and high specificity when combined with low ADAMTS13 activity levels. Multiplex bead-based assays, often utilizing Luminex xMAP technology, enable by coupling distinct ADAMTS13 domain fragments (e.g., MDTCS encompassing metalloprotease, disintegrin, thrombospondin type 1 repeats, and /spacer regions versus isolated domains) to color-coded magnetic beads for simultaneous detection of binding profiles in patient . These assays reveal the polyclonal nature of the autoimmune response, with frequent reactivity against spacer and epitopes, and provide higher resolution for research into specificity compared to single-plex . Clinically, inhibitor detection distinguishes acquired TTP (positive autoantibodies) from congenital deficiency (negative), guiding urgent plasma exchange initiation in immune-mediated cases. Persistent low-titer s or high autoantibody levels during remission predict relapse risk, with studies showing up to a threefold increased likelihood in patients with detectable inhibitors post-recovery.

Treatment

Management of acquired TTP

The management of acquired (TTP), an immune-mediated condition characterized by autoantibodies inhibiting ADAMTS13, centers on rapid intervention to remove inhibitors, replenish ADAMTS13, and prevent microvascular . Therapeutic plasma exchange (PEX) remains the cornerstone of initial therapy, established as first-line treatment following a landmark 1991 randomized demonstrating its superiority over infusion in improving survival rates from over 90% mortality to under 20%. PEX involves exchanging 1.0–1.5 volumes (typically 40–60 mL/kg body weight) daily until platelet counts normalize (≥150 × 10^9/L) and levels resolve, usually within 5–7 days in responsive cases; this procedure removes circulating autoantibodies and ultra-large multimers while supplying functional ADAMTS13 from donor . Guidelines recommend initiating PEX urgently, ideally within 4–8 hours of suspicion, using central venous access if peripheral is insufficient, and continuing for at least 2 days after platelet recovery to minimize exacerbations, which occur in up to 20–40% of cases without adjunctive measures. Adjunctive therapies enhance PEX efficacy by targeting the underlying . , a bivalent nanobody that inhibits the interaction between ultra-large and platelets by binding the domain, was approved by the FDA in 2019 for adult patients with acquired TTP in combination with PEX and . Administered subcutaneously at 11 mg as a followed by daily maintenance until PEX cessation (typically 7–10 days, with a post-PEX dose), accelerates platelet count recovery (median 2.7 days vs. 4.0 days with ) and reduces the need for PEX sessions by about 2–3 days, thereby shortening hospitalization and lowering refractory TTP risk from 38% to 13%. Real-world data confirm these benefits, with mortality rates below 5% in treated cohorts, though bleeding risks (e.g., epistaxis in 10–15%) necessitate vigilant monitoring. Immunosuppressive agents address the autoantibody production driving acquired TTP. High-dose corticosteroids, such as prednisone 1 mg/kg/day orally (or methylprednisolone 1 g/day intravenously for severe cases), are recommended alongside PEX for all acute episodes to suppress inhibitor synthesis, with tapering over 3 weeks post-remission to prevent rebound. Rituximab, an anti-CD20 monoclonal antibody depleting B cells, is indicated for refractory or relapsing cases, typically at 375 mg/m^2 weekly for 4 doses starting on day 1–3 of PEX; it achieves sustained remission in over 90% of such patients by reducing inhibitor titers within 2–4 weeks. Emerging options include IL-6 inhibitors like tocilizumab for select refractory patients unresponsive to rituximab, targeting inflammatory cytokine-driven autoimmunity, though evidence remains limited to case series showing rapid ADAMTS13 recovery in 70–80% of treated individuals. Ongoing monitoring is essential due to the high relapse risk of 30–50% over 5–10 years, particularly in patients with persistently low ADAMTS13 activity (<10% during remission). Daily assessments of platelet counts, , and ADAMTS13 levels guide PEX duration and detect exacerbations early; post-acute, ADAMTS13 monitoring every 1–3 months for the first year, then 3–6 months thereafter, informs preemptive rituximab if levels drop below 10–20%. Patients should be educated on triggers like infections or and advised to seek immediate care for symptoms such as or petechiae, with prophylactic considered for high-risk profiles to mitigate recurrence.

Therapies for congenital deficiency

The recommended primary therapy for congenital deficiency of ADAMTS13, also known as Upshaw-Schulman syndrome or congenital (cTTP), is recombinant ADAMTS13 (rADAMTS13), per the 2025 focused update to the ISTH guidelines, which strongly recommends it over plasma-derived products for prophylaxis in patients in remission to prevent acute episodes. Marketed as Adzynma (ADAMTS13, recombinant-krhn), it represents the first FDA-approved enzyme replacement specifically for cTTP, authorized on November 9, 2023, for prophylactic and use in adults and pediatric patients. For prophylactic , the recommended regimen is 40 / intravenously every other week, with potential adjustment to weekly dosing based on ADAMTS13 activity monitoring to achieve near-normal levels (approximately 100% of wild-type activity post-infusion). In acute settings, on-demand dosing starts with 40 / on day 1, followed by 20 / on day 2, and then 15 / daily from day 3 until two days after clinical resolution of the thrombotic event, offering faster recovery and fewer TTP flares compared to plasma. This avoids donor-related risks such as transmission of infections or alloimmunization, with clinical trials demonstrating sustained ADAMTS13 activity, improved , and safety even in patients with end-stage renal disease. Plasma-derived products remain an alternative for replacement of the missing , particularly when rADAMTS13 is unavailable. (FFP) infusions provide exogenous ADAMTS13 for both acute episodes and prophylaxis, typically administered at 10–15 mL/kg body weight every 1–3 weeks, adjusted based on ADAMTS13 activity to maintain trough levels above 10–20% and prevent thrombotic events. Cryosupernatant plasma, which is FFP depleted of containing multimers, serves as an alternative to reduce infusion volume and potential complications while still delivering ADAMTS13, with similar dosing regimens. However, repeated plasma infusions carry risks including , allergic reactions, and rare development of alloantibodies against ADAMTS13, which can reduce efficacy over time. Gene therapy approaches aim to provide a curative option by enabling endogenous ADAMTS13 production, primarily using (AAV) vectors to target expression in the liver. Preclinical studies in murine models of cTTP have shown sustained ADAMTS13 secretion and prevention of thrombotic phenotypes following AAV-mediated gene transfer, with ongoing research exploring human applicability as of 2025. No phase 1/2 clinical trials have advanced to by late 2025, but these efforts build on the genetic basis of biallelic ADAMTS13 mutations causing the deficiency. Supportive measures complement replacement therapies by mitigating hemolytic anemia and avoiding triggers that precipitate acute episodes. Daily folic acid supplementation (typically 1–5 mg) supports in the context of microangiopathic . Patients are advised to avoid exacerbating factors such as estrogen-containing contraceptives or therapies, which can increase levels and risk, alongside infections, , and requiring heightened monitoring.